tradingkey.logo

Anktiva® With Bcg Demonstrates 96% Survival From Bladder Cancer

ReutersDec 16, 2025 2:10 PM

- Immunitybio Inc IBRX.O:

  • ANKTIVA® WITH BCG DEMONSTRATES 96% SURVIVAL FROM BLADDER CANCER AT THREE YEARS WITH MEDIAN SURVIVAL NOT YET REACHED IN BCG-UNRESPONSIVE HIGH-GRADE PAPILLARY-ONLY NON-MUSCLE INVASIVE BLADDER CANCER

  • IMMUNITYBIO INC - ANKTIVA PLUS BCG SHOWS TOLERABLE SAFETY PROFILE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI